Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | JUN | P05412 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 11/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dehydromethoxygaertneroside SCHEMBL31180007 | 1.00 | POLB (0.58) | POLBCTDSP1JUNMEN1MAPT | |
| Dehydrogaertneroside SCHEMBL29425897 | 0.90 | POLB (0.62) | POLBCTDSP1JUNMEN1MAPT | |
| Methoxygaertneroside SCHEMBL29425775 | 0.85 | POLB (0.56) | POLBCTDSP1JUNMEN1MAPT | |
| Methoxygaertneroside SCHEMBL29425771 | 0.85 | POLB (0.56) | POLBCTDSP1JUNMEN1MAPT | |
| SCHEMBL29426062 | 0.84 | JUN (0.66) | POLBCTDSP1JUNMEN1MAPT | |
| SCHEMBL29425686 | 0.82 | POLB (0.68) | POLBCTDSP1JUNMEN1MAPT | |
| Plumieride SCHEMBL419720 | 0.80 | POLB (0.65) | POLBCTDSP1JUNMEN1MAPT | |
| Gaertneroside SCHEMBL31179982 | 0.78 | POLB (0.60) | POLBCTDSP1JUNMEN1MAPT | |
| Gaertneroside SCHEMBL420081 | 0.78 | POLB (0.60) | POLBCTDSP1JUNMEN1MAPT | |
| Galioside SCHEMBL29431810 | 0.74 | POLB (1.00) | POLBCTDSP1JUNMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702037-A1 | METHOD OF PRODUCING IRIDOIDS | Nicoventures Trading Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4626425-A1 | TARGETING INNATE IMMUNE MEMORY AND AP-1 OR ATF3 FOR THE TREATMENT OF OCULAR DISEASES | RSEM, Limited Partnership (CA) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025068418-A1 | INHIBITOR OF THE TRANSCRIPTION FACTOR AP-1 FOR USE IN THE TREATMENT OF AGE-RELATED DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024224085-A1 | METHOD OF PRODUCING IRIDOIDS | Nicoventures Trading Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024113061-A1 | TARGETING INNATE IMMUNE MEMORY AND AP-1 OR ATF3 FOR THE TREATMENT OF OCULAR DISEASES | SAPIEHA PRZEMYSLAW (CA) | 2024-06-06 | — | — | WO | disclosed |
| EP-3409766-B1 | AN ESTERASE THAT IS CAPABLE OF CONVERTING IRIDOIDS AND SECO-IRIDOIDS | N ZYME BIOTEC GMBH (DE) | 2022-03-09 | — | — | EP | disclosed |